Inhibition of platelet aggregation by anti-5-hydroxytryptaminic and alpha-adrenergic blocking agents.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D003094:Collagen / Q000037:antagonists & inhibitors; D003720:Densitometry; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004837:Epinephrine / Q000037:antagonists & inhibitors; D004873:Ergolines / Q000008:administration & dosage; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D008784:Methysergide / Q000008:administration & dosage; D009539:Nicotinic Acids / Q000008:administration & dosage; D010646:Phentolamine / Q000494:pharmacology; D010973:Platelet Adhesiveness / Q000187:drug effects*; D011817:Rabbits; D012702:Serotonin Antagonists; D013696:Temperature; D013917:Thrombin / Q000037:antagonists & inhibitors; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D004873:Ergolines; D009539:Nicotinic Acids; D012702:Serotonin Antagonists; D000244:Adenosine Diphosphate; D003094:Collagen; D013917:Thrombin; D008784:Methysergide; D004837:Epinephrine; D010646:Phentolamine